Abaloparatide is a selective parathyroid hormone-related peptide analog studied for its anabolic effects on bone. Research highlights its potential in promoting bone growth, improving mineral density, reducing fracture risk, and supporting skeletal health in experimental models.
For research purposes only. This product is supplied exclusively for scientific laboratory research and analytical purposes. It is not intended for human or animal use, and must not be misused in any way that contravenes MHRA regulations or applicable laws.
Secured and trusted checkout with
1
Free Delivery
Free delivery on all orders above £100
2
Secure Payments
Selection of secure payments
3
Support 24/7
Contact us 24 hours a day, 7 days a week
Validate your login
Abaloparatide (brand names Eladynos, Tymlos) is a highly effective, daily, self-administered injection for treating postmenopausal osteoporosis, specifically in patients at very high risk of fracture. As an anabolic agent, it stimulates bone-forming cells (osteoblasts) to significantly increase bone mineral density (BMD) and reduce spinal fracture risk by up to 88%.
Key Benefits of Abaloparatide
Significant Fracture Reduction: Studies demonstrated that abaloparatide reduced the risk of new vertebral (spine) fractures by 88% and non-vertebral fractures by 69% compared to a placebo.
Increased Bone Density: It acts as a parathyroid hormone-related peptide (PTHrP) analog, actively stimulating bone formation to increase density in the hip and spine.
Targeted Treatment for High Risk: It is approved for postmenopausal women and men with osteoporosis at high risk of fracture, including those who have already experienced a fracture.
Effective Alternative: It is considered as effective as other anabolic treatments (like teriparatide) and can be used to treat patients who have failed or cannot tolerate other osteoporosis therapies.
Clinical Efficacy: When followed by an anti-resorptive treatment (like alendronic acid), it resulted in an 84% lower risk of new vertebral fractures compared to placebo.
Reduced Hypercalcemia Risk: Compared to teriparatide, abaloparatide showed a 51% lower prevalence of hypercalcemia (excess calcium in the blood), which is a potential side effect of some bone-building drugs.
Validate your login